Trial reportJACC. Cardiovascular imaging2022
Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results.
Trial report in JACC. Cardiovascular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01174550 (PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
PROspective Multicenter Imaging Study for Evaluation of Chest Pain - The PROMISE Trial
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- Acute vascular redox modulation by SGLT2 inhibition in non-diabetic patients.Cardiovascular diabetology. Endocrinology reports · 2026Article
- Unbiased Discovery of Genetic Determinants of Resilience to CAD: Insights From PROMISE and CATHGEN.JACC. Advances · 2026Article
- The role of IL-6 in atherosclerosis: a narrative review.Frontiers in cardiovascular medicine · 2026Review
- Interleukin-6 is associated with high-risk plaque on coronary computed tomography angiography in asymptomatic women.American journal of preventive cardiology · 2025Article
- Pericoronary adipose tissue radiomics to improve risk stratification for patients with acute coronary syndrome: a multicenter retrospective cohort study.Cardiovascular diabetology · 2025Article
- Review
- Genomic medicine and personalized treatment: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Predictive Value of Selected Plasma Biomarkers in the Assessment of the Occurrence and Severity of Coronary Artery Disease.International journal of molecular sciences · 2025Article
- Inflammatory Gene Signature Identified by Machine Algorithms Reveals Novel Biomarkers of Coronary Artery Disease.Journal of inflammation research · 2025Article
- IL-6 and Cardiovascular Risk: A Narrative Review.Current atherosclerosis reports · 2024Review
- Different levels of lipids, Hb1Ac and cytokines among patients with coronary artery disease.Heliyon · 2024Article
- Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV.JACC. Advances · 2024Article
- A Multi-Biomarker Approach to Increase the Accuracy of Diagnosis and Management of Coronary Artery Disease.Journal of cardiovascular development and disease · 2024Article
- Diagnostic value and method of soluble transferrin receptor for suspected coronary artery disease: a case-control study.Cardiovascular diagnosis and therapy · 2024Article
- Coronary Artery Plaque Phenotype and 5-Year Clinical Outcomes in Older Patients with Non-ST Elevation Acute Coronary Syndrome.Reviews in cardiovascular medicine · 2024Article
- Deleterious Anti-Inflammatory Macrophage Recruitment in Early Post-Infarction Phase: Unraveling the IL-6/MCP-1/STAT3 Axis.JACC. Basic to translational science · 2024Article
- Predicting the presence of coronary plaques featuring high-risk characteristics using polygenic risk scores and targeted proteomics in patients with suspected coronary artery disease.Genome medicine · 2024Article
- Effects of coronary artery disease in patients with permanent left bundle branch area pacing: A retrospective study.Heliyon · 2024Article
- Novel imaging modalities for the identification of vulnerable plaques.Frontiers in cardiovascular medicine · 2024Review
- Association of cigarette smoking with cardiometabolic risk factors: A cross-sectional study.Tobacco induced diseases · 2024Article
Corrections and comments
- Commented on by
Authors and funding
14 authors at 8 institutions in 3 countries.
Funding
Abstract
backgroundIncreased inflammation and myocardial injury can be observed in the absence of myocardial infarction or obstructive coronary artery disease (CAD).
objectivesThe authors determined whether biomarkers of inflammation and myocardial injury-interleukin (IL)-6 and high-sensitivity cardiac troponin (hs-cTn)-were associated with the presence and extent of CAD and were independent predictors of major adverse cardiovascular events (MACEs) in stable chest pain.
methodsUsing participants from the PROMISE trial, the authors measured hs-cTn I and IL-6 concentrations and analyzed computed tomography angiography (CTA) images in the core laboratory for CAD characteristics: significant stenosis (≥70%), high-risk plaque (HRP), Coronary Artery Disease Reporting and Data System (CAD-RADS) categories, segment involvement score (SIS), and coronary artery calcium (CAC) score. The primary endpoint was a composite MACE (death, myocardial infarction, or unstable angina).
resultsThe authors included 1,796 participants (age 60.2 ± 8.0 years; 47.5% men, median follow-up 25 months). In multivariable linear regression adjusted for atherosclerotic cardiovascular disease (ASCVD) risk, hs-cTn was associated with HRP, stenosis, CAD-RADS, and SIS. IL-6 was only associated with stenosis and CAD-RADS. hs-cTn above median (1.5 ng/L) was associated with MACEs in univariable analysis (HR: 2.1 [95% CI: 1.3-3.6]; P = 0.006), but not in multivariable analysis adjusted for ASCVD and CAD. IL-6 above median (1.8 ng/L) was associated with MACEs in multivariable analysis adjusted for ASCVD and HRP (HR: 1.9 [95% CI: 1.1-3.3]; P = 0.03), CAC (HR: 1.9 [95% CI: 1.0-3.4]; P = 0.04), and SIS (HR: 1.8 [95% CI: 1.0-3.2]; P = 0.04), but not for stenosis or CAD-RADS. In participants with nonobstructive CAD (stenosis 1%-69%), the presence of both hs-cTn and IL-6 above median was strongly associated with MACEs (HR: 2.5-2.7 after adjustment for CAD characteristics).
conclusionsConcentrations of hs-cTn and IL-6 were associated with CAD characteristics and MACEs, indicating that myocardial injury and inflammation may each contribute to pathways in CAD pathophysiology. This association was most pronounced among participants with nonobstructive CAD representing an opportunity to tailor treatment in this at-risk group. (PROspective Multicenter Imaging Study for Evaluation of Chest Pain [PROMISE]; NCT01174550).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.